PAX2 and ovarian endometrioid adenocarcinoma: Marker aberrance was most frequent in endometrioid adenocarcinomas of the ovary, with PAX2 aberrance in 93.1% of cases, followed by PTEN (27.6%) and β-catenin (48.3%).